drugset / Trial / NCT05712720
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Outcome
Met primary endpoint
release “RZ402 met both primary endpoints of change in macular edema (CST) and a good safety profile” rezolutebio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RZ402 | Unknown | 50 mg | Oral |
| Subject | RZ402 | Unknown | 200 mg | Oral |
| Subject | RZ402 | Unknown | 400 mg | Oral |